Precision Oncology Pipeline — Discovery Programs

Novel Targets from Portrai ATLAS → Modality-Fit Asset Candidates

OVERVIEW

Discovery programs at a glance

Portrai’s discovery pipeline starts with Portrai ATLAS, our proprietary spatial biology database and data moat, and is translated through PortraiTARGET, our spatial transcriptomics intelligence engine for novel oncology target discovery. Each POR Series target is selected not only for expression, but for its spatial position within the tumor, selective enrichment against normal tissue, and biological fit with therapeutic modalities. From these targets, Portrai builds modality-fit asset candidates across ADC and RPT programs, while enabling future expansion into binder-based therapeutic modalities such as multispecific antibodies, TCEs, and ISACs. This allows Portrai to translate spatial cancer biology into a broader precision oncology therapeutic engine.

PROGRAM	MODALITY	TARGET	DISCOVERY
POR001	ADC	Stromal target	ADC feasibility stage
POR0011	ADC	ADC Candidate
POR003	ADC	Adenocarcinoma target	ADC feasibility stage
POR0031	ADC	ADC Candidate
POR006	ADCRPT	Cell-surface target	Discovery / Multi-asset expansion stage
POR0061	ADC	ADC Candidate
POR0063	RPT	Ab fragment–RPT Candidate
POR-TBD-A	ADC	Undisclosed	Target discovery ongoing

PROGRAMS

Targets & asset candidates

POR001

Stromal targetADCADC feasibility stage

Target

POR001 is a Portrai ATLAS-derived novel stromal target designed to unlock the next generation of tumor-stroma-directed ADCs. Highly enriched in cancer-proximal stromal regions with limited normal-tissue expression, POR001 offers more tumor-restricted localization than conventional stromal targets such as FAP.

Asset Candidate

POR0011ADC Candidate

POR0011 is a fully human IgG antibody directed against POR001 and is being evaluated for development as a stromal-targeting ADC. POR0011 exhibits low-nanomolar binding affinity, high target specificity, target-specific cellular uptake, and robust internalization, supporting its potential for ADC applications across multiple solid tumor indications.

Development Status: ADC feasibility stage

Novel target identified from Portrai ATLAS
Fully human IgG candidate secured
Binding, specificity, uptake, and internalization confirmed
ADC development path under evaluation for broad solid tumor indications

POR003

Adenocarcinoma targetADCADC feasibility stage

Target

POR003 is a Portrai ATLAS-derived novel adenocarcinoma target selected for tumor-selective expression and ADC-compatible biology. Enriched in colorectal and pancreatic adenocarcinomas with limited normal-tissue expression, POR003 is positioned as a differentiated adenocarcinoma ADC target for tumors where deeper and more selective payload delivery remains a major unmet need.

Asset Candidate

POR0031ADC Candidate

POR0031 is a fully human IgG antibody directed against POR003. With nanomolar binding affinity and robust internalization, POR0031 is being evaluated as an adenocarcinoma-targeting ADC for colorectal and pancreatic cancers.

Key Highlights

Portrai ATLAS-derived novel adenocarcinoma target
Tumor-selective expression in CRC and PDAC
Limited normal-tissue expression profile
ADC-compatible biology with robust internalization
Lead adenocarcinoma ADC program for colorectal and pancreatic cancers

POR006

Cell-surface targetADCRPTDiscovery / Multi-asset expansion stage

Target

POR006 is a Portrai ATLAS-derived novel cell-surface target with broad expression across squamous cell carcinomas and limited normal-tissue expression. With strong SqCC coverage, accessible cell-surface biology, and compatibility across multiple therapeutic modalities, POR006 is positioned as a high-value target for building both ADC and RPT programs.

Asset Candidates

POR0061ADC Candidate

POR0061 is a fully human IgG-based ADC candidate directed against POR006. With sub-nanomolar binding affinity, POR0061 is being developed as a SqCC-focused ADC candidate designed to leverage broad POR006 expression across squamous cancers.

POR0063Ab fragment–RPT Candidate

POR0063 is an antibody fragment–based RPT candidate directed against POR006. By combining antibody-fragment specificity with an RPT-compatible format, POR0063 is being developed as an additional precision radiopharmaceutical strategy for squamous cell carcinomas.

Development Status: Discovery / Multi-asset expansion stage

Novel SqCC-enriched target identified from Portrai ATLAS
Fully human IgG lead identified for ADC development
Antibody fragment–based RPT program under development
Multi-modality development path across ADC and RPT

PARTNERSHIP

Partner with Portrai for early out-licensing

Portrai's pipeline assets are validated with spatial biology and AI-driven insights. We are seeking strategic partnerships to accelerate clinical development.

Co-Discovery

Leverage Portrai's platform to find novel targets for your specific modalities.

Asset Licensing

Access pre-clinical POR-series assets on a path toward IND-enabling studies.

Modality Expansion

Parallel validation for ADCs, RPTs, and T-cell engagers.

LET'S TALK

Ready to accelerate your oncology pipeline?

Connect with our Business Development team to discuss licensing opportunities, view confidential data rooms, or explore co-discovery partnerships.

Contact BD Team